---
title: "Early Breast Cancer (EBC) Treatment | Kisqali®"
description: "Discover the proven efficacy and demonstrated risk reduction of KISQALI® for HR+/HER2- early breast cancer (EBC) in both postmenopausal and premenopausal patients, with significant invasive disease-free survival benefits and a manageable safety profile"
canonical_url: "https://www.kisqali.com/early-breast-cancer"
meta:
  "og:description": "Discover the proven efficacy and demonstrated risk reduction of KISQALI® for HR+/HER2- early breast cancer (EBC) in both postmenopausal and premenopausal patients, with significant invasive disease-free survival benefits and a manageable safety profile"
  "og:title": "Early Breast Cancer (EBC) Treatment"
---

## **Proven efficacy**

![Fictional portrait of a smiling white  woman used in the Natelee breast cancer study .](https://www.kisqali.com/img/early-breast-cancer/mobile/natalee-study-woman-portrait.webp)

NATALEE

**KISQALI + AI in pre- and postmenopausal patients**

visibility

Latest clinical data

Discover the latest clinical data:

KISQALI: with OS benefit across  
 all phase III trials in both EBC and ABC

## **Give more of your patients **<br>** news worth sharing **

### **In HR+/HER2- EBC iDFS benefit with KISQALI + NSAI ***vs*** NSAI alone: **

![Fictional patient and caregiver smiling while talking about KISQALI® treatment for advanced breast cancer.](https://www.kisqali.com/img/early-breast-cancer/ebc-patient-conversation.webp)

[<h3>check\_circleReduced the risk of recurrence<sup>(1)</sup></h3>At 3 years, the risk of invasive disease was reduced by 25%\*](https://www.kisqali.com/early-breast-cancer/risk-of-recurrence) [<h3>check\_circleApproved in the broadest population<sup>(2,3)</sup></h3>including all N+ and high-risk N0 patients](https://www.kisqali.com/early-breast-cancer/health-related-quality-of-life) [<h3>check\_circleManageable safety profile and maintained quality of life (QOL)<sup>‡(3,4)</sup></h3>](https://www.kisqali.com/early-breast-cancer/safety-data/adverse-events)

## **For Healthcare Professionals Outside the US**

KISQALI is indicated in the EU for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.  
  
 KISQALI in combination with an aromatase inhibitor is indicated in the EU for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence. In pre- or perimenopausal women, or in men, the aromatase inhibitor should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.

![City river view encouraging healthcare professionals to access country-specific NovartisPro information.](https://www.kisqali.com/img/early-breast-cancer/mobile/local-hcp-portal.webp)

**Visit your local HCP portal for further country specific information**

This website is intended for Health Care Professionals (HCPs) outside the US and Switzerland. The information on this website is not country specific and may contain information that is outside the approved indication in the country in which you are located. Please contact your local representative for local prescribing information. By clicking continue you are confirming that you are an HCP.

## Sitemap

See the full [sitemap](/sitemap.md) for all pages.